CLINICAL_TRIALS
trial_result
· 2022-06-16
Clinical Trial Update: MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma [Phase 2]
Summary
Phase 2 clinical trial update evaluating MTG201 plus nivolumab for relapsed malignant pleural mesothelioma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Momotaro-Gene Inc. | Conditions: Malignant Pleural Mesothelioma | Phase 2 | Status: UNKNOWN